Literature DB >> 8619004

Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence.

P A LeDuc1, G Mittleman.   

Abstract

The authors selected articles from those published between 1975 and 1994 that specifically documented psychostimulant abuse in patients determined to be schizophrenic according to recent and relatively uniform diagnostic criteria. These articles indicated that the incidence of psychostimulant abuse in schizophrenics is 2-5 times higher than that of the general public. Additionally, unlike the decline in stimulant use seen in older adults in the general population, high rates of abuse appeared to be maintained in schizophrenics. Although the incidence of abuse in this group was high, comparisons of abuse rates generated by self report with those obtained by urinalysis indicated that the frequency of abuse is being underestimated by 15-21%. Potential factors contributing to stimulant abuse in schizophrenics, including the disease process, and the influence of chronic neuroleptic medication, were evaluated. Results indicated that the incidence of psychostimulant abuse was neither a common property of psychiatric patients, nor exclusive to schizophrenics, but appeared to be related to chronic treatment with neuroleptic drugs. Symptom severity was generally similar in schizophrenic abusers and non-abusers, which also suggested a degree of independence from the disease process. In a majority of the studies surveyed, abuse of stimulants followed disease onset. It was also found that stimulant abuse was associated with marked increases in hospitalization in this patient group, including those known to be neuroleptic medication compliant. Possible explanations for the initiation and maintenance of psychostimulant abuse in schizophrenics are discussed in relation to clinical and preclinical evidence on drug addiction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8619004     DOI: 10.1007/bf02246489

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  102 in total

1.  Substance use in young adults with schizophrenic disorders.

Authors:  M A Test; L S Wallisch; D J Allness; K Ripp
Journal:  Schizophr Bull       Date:  1989       Impact factor: 9.306

2.  Dextroamphetamine. Evaluation of psychomimetic properties in man.

Authors:  J D Griffith; J Cavanaugh; J Held; J A Oates
Journal:  Arch Gen Psychiatry       Date:  1972-02

3.  Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy.

Authors:  D S Segal; A J Mandell
Journal:  Pharmacol Biochem Behav       Date:  1974 Mar-Apr       Impact factor: 3.533

4.  Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.

Authors:  J M Cleghorn; R D Kaplan; B Szechtman; H Szechtman; G M Brown; S Franco
Journal:  J Clin Psychiatry       Date:  1991-01       Impact factor: 4.384

5.  The pharmacological and anatomical substrates of the amphetamine response in the rat.

Authors:  I Creese; S D Iversen
Journal:  Brain Res       Date:  1975-01-17       Impact factor: 3.252

6.  Unrecognized cocaine use among schizophrenic patients.

Authors:  A Shaner; M E Khalsa; L Roberts; J Wilkins; D Anglin; S C Hsieh
Journal:  Am J Psychiatry       Date:  1993-05       Impact factor: 18.112

7.  Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms.

Authors:  D S Janowsky; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1976-03

8.  Recent psychostimulant use in hospitalized schizophrenics.

Authors:  M L Richard; B I Liskow; P J Perry
Journal:  J Clin Psychiatry       Date:  1985-03       Impact factor: 4.384

9.  Neurobiological vulnerability to low-dose amphetamine psychosis.

Authors:  M S Gold; M B Bowers
Journal:  Am J Psychiatry       Date:  1978-12       Impact factor: 18.112

10.  Substance abuse in an inpatient psychiatric sample.

Authors:  K Brady; S Casto; R B Lydiard; R Malcolm; G Arana
Journal:  Am J Drug Alcohol Abuse       Date:  1991       Impact factor: 3.829

View more
  14 in total

Review 1.  Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.

Authors:  Tong H Lee; Steven T Szabo; J Corey Fowler; Paolo Mannelli; O Barry Mangum; Wayne F Beyer; Ashwin Patkar; William C Wetsel
Journal:  Drug Alcohol Depend       Date:  2012-02-21       Impact factor: 4.492

2.  Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood.

Authors:  Zackary A Cope; Kimberly N Huggins; A Brianna Sheppard; Daniel M Noel; David S Roane; Russell W Brown
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

3.  Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

4.  An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics.

Authors:  D S Segal; R Kuczenski
Journal:  J Neurosci       Date:  1997-04-01       Impact factor: 6.167

5.  Reaction time variability and related brain activity in methamphetamine psychosis.

Authors:  Catherine Fassbender; Tyler A Lesh; Stefan Ursu; Ruth Salo
Journal:  Biol Psychiatry       Date:  2014-08-07       Impact factor: 13.382

6.  Nitric oxide synthesis inhibition attenuates haloperidol-induced supersensitivity.

Authors:  C M Pudiak; M A Bozarth
Journal:  J Psychiatry Neurosci       Date:  1997-01       Impact factor: 6.186

Review 7.  A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.

Authors:  Martin Sarter; Vicente Martinez; Rouba Kozak
Journal:  Psychopharmacology (Berl)       Date:  2008-07-10       Impact factor: 4.530

8.  Nicotine sensitization in adult male and female rats quinpirole-primed as neonates.

Authors:  Marla K Perna; Zackary A Cope; Amanda M Maple; Ian D Longacre; Jennifer A Correll; Russell W Brown
Journal:  Psychopharmacology (Berl)       Date:  2008-06-12       Impact factor: 4.530

9.  Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

10.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.